Dionex soars on Thermo Fisher buyout. After the bell: Amgen higher on strong cancer study data, Genoptix puts itself up for sale Print E-mail
By BioMedReports.com Staff   
Monday, 13 December 2010 19:36

 

Below is a look at some of the headlines for companies that made news in the healthcare sector on December 13, 2010.

After the bell, shares of Amgen (Nasdaq:AMGN) surged higher after the company announced top-line results from a Phase 3 trial evaluating XGEVA versus placebo in 1,432 men with castrate-resistant prostate cancer. The drug, also known as denosumab, showed an improvement in bone metastasis-free survival by 4.2 months. The secondary endpoint, overall survival, however, was similar between the drug and placebo groups. Analysts are forecasting sales of XGEVA as high as $2.5 billion by 2014.

Shares of Amgen jumped $3.98 or 7.36% to $58.09 in extended trading.

Also after the bell, shares of Genoptix, Inc. (NASDAQ:GXDX) jumped 16% or $3.02 after Bloomberg reported that the company has said to seek buyers and has hired Barclays to conduct an auction. Shares closed the after hours session at $21.00.

Earlier Monday, Thermo Fisher Scientific (NYSE:TMO), the worlds largest maker of scientific instruments announced that it will acquire Dionex Corporation (NASDAQ:DNEX), a leading manufacturer and marketer of chromatography systems, for $118.50 per share in cash, or a total purchase price of approximately $2.1 billion. Chromatography systems are used in the analysis in areas such as drug compounds as well as water quality and food contaminants.

Dionex surged $19.66 or 20% to $117.83 while shares of Thermo Fisher jumped $2.52 or 4.75% to $55.56.

Also Monday:

China Cord Blood Corporation (NYSE:CO) the first and largest cord blood banking operator in China, today announced the completion of its previously announced warrant exchange offer, which allowed warrant holders to receive one ordinary share for every eight warrants outstanding.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today will provide investors with information on the initiatives expected to result in double-digit sales growth in 2011.

First China Pharmaceutical Group, Inc. (OTCBB:FCPG) , a rapidly growing pharmaceutical distribution company headquartered in Yunnan, China, was extremely pleased by recent reports from the official Xinhua news agency regarding announcements from the Chinese Central Government declaring new policies to encourage private funds, including overseas capital, to be channeled into the medical sector to meet the country's increasingly diversified demands on health care.

FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, announced today that a provider of outpatient diagnostic services (a FONAR customer) and several Stand-Up MRI diagnostic imaging professional corporations (PCs) received a jury verdict in their favor in an anti-trust lawsuit against CareCore National, LLC, a radiology benefits management (RBM) company.

Generex Biotechnology Corporation (OTC Bulletin Board:GNBT) announced today that the peer-reviewed scientific journal Diabetes, Obesity and Metabolism has published new positive data in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

Genomic Health, Inc. (Nasdaq:GHDX) today announced results from seven new studies focusing on its multigene Oncotype DX® breast cancer test, which has helped guide treatment decisions in more than 175,000 breast cancer patients worldwide.

Health Enhancement Products, Inc. (HEPI) (OTCBB: HEPI) announced today that it has received its first purchase order from the contract that it completed with Zus Health, LLC (Zus) for ProAlgaZyme® (PAZ™).

MMRGlobal, Inc. (OTCBB:MMRF) ("MMR") today announced that Sunil Singhil has been named Executive Vice President and a member of the Executive Committee, succeeding Rich Teich, who will focus on the sales, marketing and installation support for MMRPro and MMRPatientView, the Company's professional health IT products for physicians, small hospitals and healthcare professionals.

Proteonomix, Inc. (OTCBB: PROT) notes the favorable similarity between technology involved in the Cephalon, Inc. (CEPH) transaction with Australian company Mesoblast Limited.

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics announces today the commercial availability of miRview® mets² ("miRview mets two"), a microRNA-based test that identifies the primary origin of tumors of uncertain or unknown origin.

Sangamo BioSciences, Inc. (Nasdaq:SGMO) announced the publication of preclinical data demonstrating protection of nerve tissue and functional improvements in motor symptoms in a validated rat model of Parkinson's disease (PD) using Sangamo's zinc finger protein (ZFP) technology.

YM BioSciences Inc. (NYSE Amex:YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that it intends to offer and sell shares of its common shares in an underwritten public offering.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter